Analysis of pik3ca mutations in breast cancer subtypes

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 1, 2014, Pages 50-56

  Arsenic, Ruza ^a   Lehmann, Annika ^a   Budczies, Jan ^a   Koch, Ines ^a   Prinzler, Judith ^a   Kleine Tebbe, Anke ^b   Schewe, Christiane ^a   Loibl, Sibylle ^c   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Breast Cancer Center   (Germany)

^c German Breast Group   (Germany)

Author keywords

breast cancer; mutation status; PIK3CA

Indexed keywords

CELL DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PRIMER DNA; UNCLASSIFIED DRUG;

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; DNA EXTRACTION; ENZYME ACTIVE SITE; EXON; EXON 20; EXON 9; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; MUTATION RATE; NONSENSE MUTATION; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BREAST NEOPLASMS; COHORT STUDIES; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84891713270     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0b013e318297afea     Document Type: Article

References (55)

1. Zhao L, Vogt PK, Class I. PI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486-5496.
2. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA. 1997;94:4330-4335. (Pubitemid 27194241)
3. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562-4567. (Pubitemid 40740791)
4. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 2005;102:802-807. (Pubitemid 40282746)
5. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240-4245. (Pubitemid 29190320)
6. Celebi JT, Shendrik I, Silvers DN, et al. Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet. 2000;37:653-657.
7. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378. (Pubitemid 28268370)
8. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem. 2001;70: 247-279. (Pubitemid 32662211)
9. Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001;28(suppl 16):125-141. (Pubitemid 33065118)
10. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997;57:4183-4186. (Pubitemid 27413419)
11. Wishart MJ, Taylor GS, Slama JT, et al. PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench. Curr Opin Cell Biol. 2001;13:172-181. (Pubitemid 32209218)
12. Yokoyama Y, Wan X, Shinohara A, et al. Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med. 2000;6:47-50.
13. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226-235. (Pubitemid 40070814)
14. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:1133-1141. (Pubitemid 39207049)
15. Jordan NJ, Gee JM, Barrow D, et al. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 2004;87:167-180. (Pubitemid 39237793)
16. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311. (Pubitemid 39209661)
17. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167. (Pubitemid 39100331)
18. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol. 2006;208:350-355. (Pubitemid 43210521)
19. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681. (Pubitemid 39446895)
20. Li SY, Rong M, Grieu F, et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96:91-95.
21. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13(pt 1):408-414. (Pubitemid 46225343)
22. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554-2559. (Pubitemid 40490050)
23. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3:772-775. (Pubitemid 41351083)
24. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875-2878. (Pubitemid 40525186)
25. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15:5049-5059.
26. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177:1647-1656.
27. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107:10208-10213.
28. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-6091.
29. Frierson HF Jr, Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103:195-198.
30. Christgen M, Noskowicz M, Schipper E, et al. Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer. 2013;52:69-80.
31. Michelucci A, Di Cristofano C, Lami A, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol. 2009;18:200-205.
32. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:10992-11000. (Pubitemid 41713369)
33. Zhang H, Liu G, Dziubinski M, et al. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat. 2008;112:217-227.
34. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat. 2010;120:409-418.
35. Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol. 2010;88:150-155.
36. Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010;70:5674-5678.
37. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. (Pubitemid 38541907)
38. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477-1480. (Pubitemid 40343128)
39. Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317:239-242. (Pubitemid 47076198)
40. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA. 2008;105: 2652-2657. (Pubitemid 351520568)
41. Mandelker D, Gabelli SB, Schmidt-Kittler O, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci USA. 2009; 106:16996-17001.
42. Lai YL, Mau BL, Cheng WH, et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15:1064-1069.
43. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615-675. (Pubitemid 33096187)
44. Mizoguchi M, Nutt CL, Mohapatra G, et al. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004;14:372-377. (Pubitemid 39524966)
45. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005;114:242-248. (Pubitemid 40194293)
46. Volinia S, Hiles I, Ormondroyd E, et al. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics. 1994;24:472-477.
47. Wallin JJ, Guan J, Edgar KA, et al. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One. 2012;7:e36402.
48. Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ER alpha, PR and ERBB2-based subgroups. Breast Cancer Res. 2012;14:R28.
49. Boyault S, Drouet Y, Navarro C, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 2012;132:29-39.
50. Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064-6069. (Pubitemid 350075063)
51. Mangone FR, Bobrovnitchaia IG, Salaorni S, et al. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics. 2012;67:1285-1290.
52. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
53. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
54. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
55. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1:707-717.